Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice

Leukemia and Lymphoma

Volumn 47, Issue 9, 2006, Pages 1747-1753

  Yanada, Masamitsu ^a   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute lymphoblastic leukemia; BCR ABL; Imatinib; Philadelphia chromosome

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; MYELOABLATIVE AGENT; NILOTINIB; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLAST CELL CRISIS; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE CALCULATION; DRUG MEGADOSE; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INFECTION; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; LIVER TOXICITY; MAINTENANCE THERAPY; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; MYELOABLATIVE CONDITIONING; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; PIPERAZINES; PYRIMIDINES;

EID: 33750470841     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600634085     Document Type: Review

References (57)

1. Larson, R and Dodge, R and Burns, C and Lee, E and Stone, R and Schulman, P and (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811 Blood, 85, pp. 2025-2037.
2. Anonymous. (1996) Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique Blood, 87, pp. 3135-3142.
3. Secker-Walker, L and Prentice, H and Durrant, J and Richards, S and Hall, E and Harrison, G. (1997) Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party Br J Haematol, 96, pp. 601-610.
4. Ueda, T and Miyawaki, S and Asou, N and Kuraishi, Y and Hiraoka, A and Kuriyama, K and (1998) Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group Int J Hematol, 68, pp. 279-289.
5. Wetzler, M and Dodge, R and Mrozek, K and Carroll, A and Tantravahi, R and Block, A and (1999) Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience Blood, 93, pp. 3983-3993.
6. Faderl, S and Kantarjian, H and Thomas, D and Cortes, J and Giles, F and Pierce, S and (2000) Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia Leuk Lymphoma, 36, pp. 263-273.
7. Thomas, X and Danaila, C and Le, Q and Sebban, C and Troncy, J and Charrin, C and (2001) Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: A single institution experience of 378 consecutive patients over a 21-year period Leukemia, 15, pp. 1811-1822.
8. Gleissner, B and Gokbuget, N and Bartram, C and Janssen, B and Rieder, H and Janssen, J and (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis Blood, 99, pp. 1536-1543.
9. Takeuchi, J and Kyo, T and Naito, K and Sao, H and Takahashi, M and Miyawaki, S and (2002) Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study Leukemia, 16, pp. 1259-1266.
10. Annino, L and Vegna, M and Camera, A and Specchia, G and Visani, G and Fioritoni, G and (2002) Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study Blood, 99, pp. 863-871.
11. Chao, N and Blume, K and Forman, S and Snyder, D. (1995) Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, 85, pp. 3353-3354.
12. Cornelissen, J and Carston, M and Kollman, C and King, R and Dekker, A and Lowenberg, B and (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome Blood, 97, pp. 1572-1577.
13. Yanada, M and Naoe, T and Iida, H and Sakamaki, H and Sakura, T and Kanamori, H and (2005) Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: Significant roles of total body irradiation and chronic graft-versus-host disease Bone Marrow Transplant, 36, pp. 867-872.
14. Druker, B and Sawyers, C and Kantarjian, H and Resta, D and Reese, S and Ford, J and (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med, 344, pp. 1038-1042.
15. Ottmann, O and Druker, B and Sawyers, C and Goldman, J and Reiffers, J and Silver, R and (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias Blood, 100, pp. 1965-1971.
16. Hermans, A and Heisterkamp, N and von Linden, M and van Baal, S and Meijer, D and van der Plas, D and (1987) Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia Cell, 51, pp. 33-40.
17. Chan, L and Karhi, K and Rayter, S and Heisterkamp, N and Eridani, S and Powles, R and (1987) A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia Nature, 325, pp. 635-637.
18. Clark, S and McLaughlin, J and Timmons, M and Pendergast, A and Ben-Neriah, Y and Dow, L and (1988) Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL) Science, 239, pp. 775-777.
19. Lugo, T and Pendergast, A and Muller, A and Witte, O. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science, 247, pp. 1079-1082.
20. Yanada, M and Takeuchi, J and Sugiura, I and Akiyama, H and Usui, N and Yagasaki, F and (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group J Clin Oncol, 24, pp. 460-466.
21. Armstrong, S and Look, A. (2005) Molecular genetics of acute lymphoblastic leukemia J Clin Oncol, 23, pp. 6306-6315.
22. Faderl, S and Kantarjian, H and Talpaz, M and Estrov, Z. (1998) Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia Blood, 91, pp. 3995-4019.
23. Pui, C and Evans, W. (2006) Treatment of acute lymphoblastic leukemia N Engl J Med, 354, pp. 166-178.
24. Schrappe, M and Arico, M and Harbott, J and Biondi, A and Zimmermann, M and Conter, V and (1998) Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome Blood, 92, pp. 2730-2741.
25. Roy, A and Bradburn, M and Moorman, A and Burrett, J and Love, S and Kinsey, S and (2005) Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: Results of the Medical Research Council ALL 97 trial Br J Haematol, 129, pp. 35-44.
26. Barrett, A and Horowitz, M and Ash, R and Atkinson, K and Gale, R and Goldman, J and (1992) Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, 79, pp. 3067-3070.
27. Stockschlader, M and Hegewisch-Becker, S and Kruger, W and Tom Dieck, A and Mross, K and Hoffknecht, M and (1995) Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia Bone Marrow Transplant, 16, pp. 663-667.
28. Sierra, J and Radich, J and Hansen, J and Martin, P and Petersdorf, E and Bjerke, J and (1997) Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, 90, pp. 1410-1414.
29. Marks, D and Bird, J and Cornish, J and Goulden, N and Jones, C and Knechtli, C and (1998) Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia J Clin Oncol, 16, pp. 931-936.
30. Snyder, D and Nademanee, A and O'Donnell, M and Parker, P and Stein, A and Margolin, K and (1999) Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission Leukemia, 13, pp. 2053-2058.
31. Arico, M and Valsecchi, M and Camitta, B and Schrappe, M and Chessells, J and Baruchel, A and (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia N Engl J Med, 342, pp. 998-1006.
32. Dombret, H and Gabert, J and Boiron, J and Rigal-Huguet, F and Blaise, D and Thomas, X and (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial Blood, 100, pp. 2357-2366.
33. Esperou, H and Boiron, J and Cayuela, J and Blanchet, O and Kuentz, M and Jouet, J and (2003) A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from the French Bone Marrow Transplantation Society Bone Marrow Transplant, 31, pp. 909-918.
34. Lee, S and Kim, D and Cho, B and Kim, Y and Kim, Y and Hwang, J and (2003) Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: The potential of real-time quantitative reverse-transcription polymerase chain reaction Br J Haematol, 120, pp. 145-153.
35. Stirewalt, D and Guthrie, K and Beppu, L and Bryant, E and Doney, K and Gooley, T and (2003) Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation Biol Blood Marrow Transplant, 9, pp. 206-212.
36. Dunlop, L and Powles, R and Singhal, S and Treleaven, J and Swansbury, G and Meller, S and (1996) Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia Bone Marrow Transplant, 17, pp. 365-369.
37. Atta, J and Fauth, F and Keyser, M and Petershofen, E and Weber, C and Lippok, G and (2000) Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: Comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction Bone Marrow Transplant, 25, pp. 97-104.
38. Druker, B and Tamura, S and Buchdunger, E and Ohno, S and Segal, G and Fanning, S and (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med, 2, pp. 561-566.
39. Savage, D and Antman, K. (2002) Imatinib mesylate - a new oral targeted therapy N Engl J Med, 346, pp. 683-693.
40. Druker, B and Talpaz, M and Resta, D and Peng, B and Buchdunger, E and Ford, J and (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med, 344, pp. 1031-1037.
41. O'Brien, S and Guilhot, F and Larson, R and Gathmann, I and Baccarani, M and Cervantes, F and (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med, 348, pp. 994-1004.
42. Hughes, T and Kaeda, J and Branford, S and Rudzki, Z and Hochhaus, A and Hensley, M and (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med, 349, pp. 1423-1432.
43. Thomas, D and Faderl, S and Cortes, J and O'Brien, S and Giles, F and Kornblau, S and (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood, 103, pp. 4396-4407.
44. Thomas, D and Faderl, S and Cortes, J and O'Brien, S and Giles, F and Garcia-Manelo, G and (2005) Outcome with the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) Blood, 106. abstract #1830
45. Towatari, M and Yanada, M and Usui, N and Takeuchi, J and Sugiura, I and Takeuchi, M and (2004) Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Blood, 104, pp. 3507-3512.
46. Lee, S and Kim, Y and Min, C and Kim, H and Eom, K and Kim, D and (2005) The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, 105, pp. 3449-3457.
47. Lee, K and Lee, J and Choi, S and Lee, J and Seol, M and Lee, Y and (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Leukemia, 19, pp. 1509-1516.
48. Ottmann, O and Wassmann, B and Pfeifer, H and Goekbuget, N and Bug, G and Brueck, P and (2004) Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (PH+ALL) Blood, 104. abstract #685
49. Pfeifer, H and Ottmann, O and Goekbuget, N and Wunderle, L and Brueck, P and Giagounidis, A and (2005) A randomized phase II study of single-agent imatinib versus chemotherapy therapy in elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) including analysis of resistance patterns Blood, 106. abstract #1824
50. Vignetti, M and Fazi, P and Meloni, G and Chiarenza, A and Malagola, M and Fabbiano, F and (2004) Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients: Results of the GIMEMA prospective study LAL0201 Blood, 104. abstract #2739
51. Delannoy, A and Lheritier, V and Thomas, X and Castaigne, S and Rigal-Huguet, F and Raffoux, E and (2005) Treatment of Philadelphia-positive acute lymphocytic leukemia (Ph+ ALL) in the elderly with imatinib mesylate (STI571) and chemotherapy Blood, 106. abstract #146
52. Kantarjian, H and Talpaz, M and O'Brien, S and Garcia-Manero, G and Verstovsek, S and Giles, F and (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood, 103, pp. 2873-2878.
53. Dombret, H and Witz, F and de Botton, S and Cayuela, J and Delabesse, E and Preudhomme, C and (2004) Imatinib combined with intensive HAM chemotherapy as consolidation of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). Preliminary results of the AFR03 phase I/II study Blood, 104. abstract #2741
54. Shimoni, A and Kroger, N and Zander, A and Rowe, J and Hardan, I and Avigdor, A and (2003) Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias Leukemia, 17, pp. 290-297.
55. Kantarjian, H and Ottmann, O and Cortes, J and Wassman, B and Wunderle, L and Bhalla, K and (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph+ ALL) Blood, 106. abstract #37
56. Sawyers, C and Kantarjian, H and Shah, N and Cortes, J and Paquette, R and Donato, N and (2005) Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: Update of a phase I study Blood, 106. abstract #38
57. Ottmann, O and Martinelli, G and Dombret, H and Kantarjian, H and Hochhaus, A and Simonsson, B and (2005) A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: The 'START-L' CA180015 study Blood, 106. abstract #42